Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 26
- Publication type:
- Article
Works matching IS 21644403 AND DT 2022 AND VI 12 AND IP 7
Results: 16
1
2
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 25
- Publication type:
- Article
3
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 25
- Publication type:
- Article
4
Tibsovo Received a New Indication, in Combination with Onureg, for Newly Diagnosed Patients with AML and IDH1 Mutation.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 24
- Publication type:
- Article
5
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 24
- Publication type:
- Article
6
Biden May Stop His Cancer Moonshot's Launch.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 22
- By:
- Publication type:
- Article
7
Fertility Preservation in Patients with Cancer: How Navigators Can Get the Ball Rolling.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 20
- Publication type:
- Article
8
Neoadjuvant Chemoimmunotherapy May Become New Standard of Care for Patients with Resectable NSCLC.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 18
- By:
- Publication type:
- Article
9
AAM Calls for Federal Trade Commission to Investigate PBM Business Practices.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 16
- By:
- Publication type:
- Article
10
Adding Ibrutinib to Chemoimmunotherapy Improves PFS in Older Patients with Newly Diagnosed Mantle-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 11
- By:
- Publication type:
- Article
11
Acalabrutinib Shows Promise in Patients with Marginal Zone Lymphoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 10
- By:
- Publication type:
- Article
12
Dostarlimab Demonstrates 100% Complete Response Rate in Subset of Patients with dMMR Rectal Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 8
- By:
- Publication type:
- Article
13
Genmab: Scaling with Purpose, Precision, and Agility to Serve Patients, Physicians, and Payers.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 2
- Publication type:
- Article
14
Refueling When Your Emotional Tank Is Empty: Addressing Healthcare Worker Burnout.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 1
- By:
- Publication type:
- Article
15
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 1
- By:
- Publication type:
- Article
16
ASCO President Stresses the Importance of Innovation for Advancing Equitable Cancer Care.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 7, p. 1
- By:
- Publication type:
- Article